This is a paid press release. Contact the press release distributor directly with any inquiries.
OliX’s OLX501A Demonstrates Greater Visceral Fat Reduction Relative to a Global Comparator in Obese Non-Human Primates
Business Wire
Thu, July 30, 2026 at 6:30 PM GMT+5:30
4 min read
- 226950.KQ
-4.89%
Head-to-head study in obese non-human primates showed a 29.2% reduction in visceral fat with OLX501A versus 10.0% with a global comparator, after adjustment for baseline values and food intake
Robust and sustained pharmacodynamic activity supports the potential for a differentiated profile as an RNAi-based obesity therapy
Data suggests the potential for selective fat reduction and improved body composition, which may support future partnering and out-licensing discussions
SEOUL, South Korea, July 30, 2026–(BUSINESS WIRE)–OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced new preclinical data from a head-to-head study in obese non-human primates showing that OLX501A, its ALK7-targeting obesity program, achieved greater visceral fat reduction relative to a globally developed comparator compound. These findings add to the growing body of evidence supporting the potential of OLX501A to deliver a differentiated body-composition profile among next-generation obesity therapies.
The study was conducted in obese monkeys selected based on predefined criteria for body weight and body fat. OLX501A and the comparator were each administered subcutaneously at 3 mg/kg, with two doses given one month apart. Study endpoints included target gene knockdown, changes in visceral fat volume assessed by MRI, and pharmacodynamic biomarker responses
At Day 49, MRI analysis showed that after adjustment for baseline values and food intake, visceral fat volume in the OLX501A group was reduced by 29.2%. Under the same conditions, the comparator group showed a 10.0% reduction, while visceral fat increased by 11.1% in the control group over the study period. These findings suggest a differentiated effect of OLX501A on visceral fat reduction in this study setting
At Day 70, ALK7 mRNA knockdown measured in subcutaneous adipose tissue reached approximately 90% in the OLX501A group, a level generally comparable to that observed with the comparator. Despite generally similar target engagement in subcutaneous fat, OLX501A showed greater reduction in visceral fat, suggesting that its pharmacology may translate target inhibition into meaningful effects on fat metabolism
Pharmacodynamic biomarker analyses further supported the differentiated activity profile of OLX501A. Expression of ADRB3, a downstream biomarker associated with lipolysis following ALK7 inhibition, was approximately two-fold higher in the OLX501A group than in the comparator group at Day 28, and this difference was maintained at Day 70. Taken together, these data support the potential for robust and sustained pharmacodynamic activity in adipose tissue
